A meta-analysis of serious adverse events across different phases of clinical trials

Abstract: Understanding serious adverse events (SAEs) across clinical trial phases is crucial for assessing drug safety and ensuring participant protection. This meta-analysis examined SAE data from 120 clinical trials, spanning Phase I to Phase IV, to identify trends and risk factors associated with SAEs. A comprehensive search of databases identified relevant studies, with inclusion criteria focusing on trials that reported SAEs and used consistent definitions. Statistical analyses were performed to assess SAE incidence and variations across phases, therapeutic areas, demographics, and regions. Key findings revealed a progressive increase in SAE rates from Phase I (1.5%) to Phase III (7.0%), with oncology and cardiovascular trials showing the highest SAE incidences. Phase IV trials provided insights into rare and delayed SAEs, highlighting the need for continued monitoring postapproval. Demographic factors, such as age and gender, as well as regional differences, further impacted SAE rates. The findings emphasize the importance of robust safety protocols, risk stratification, and standardized SAE reporting across trials. Future research should focus on harmonizing SAE definitions and leveraging real-time monitoring technologies to enhance early detection and risk management, ultimately improving drug safety and clinical trial design.